RESEARCH PROJECTS

  UMDNJ - Division of Addiction Psychiatry is conducting a research study on African American non-menthol and menthol cigarette smokers. The study will examine nicotine levels and metabolism in African American smokers. Participants of the study will be compensated $50 for their time. To be qualified for the study, participants need to be a healthy African American between the ages of 18-75 who smoke 10 or more cigarettes a day. For more information or to make an appointment, participants may call 732-235-4600.

Location of the Study: 317 George Street, Suite 105 New Brunswick, NJ 08901

Posted: March 2, 2010

  Students with psychiatric disabilities often struggle with staying in college, therefore, UMDNJ and University of Pennsylvania are looking for college students between 18 -64 to participate in a research project exploring the effects of additional supports on college retention. The project seeks to identify the critical supports students with psychiatric disabilities need to be successful in college. Students must have a diagnosis of major depression, bipolar, schizophrenia, or schizoaffective disorder. Participation is confidential and compensated.

For more information please contact 1-866-788-1947 or email, psych_research@umdnj.edu

Posted: October 9, 2009

  UMDNJ-Robert Wood Johnson Medical School, Department of Psychiatry, is conducting a research study to see if there are differences in ways that different groups of people smoke cigarettes and their nicotine intake. NOT ALL STUDIES REQUIRE SUBJECTS TO STOP SMOKING.

   - "Nicotine Intake in Smokers with Schizophrenia", recruiting healthy adults
   - "Nicotine Intake in Smokers with Schizophrenia", recruiting adults with schizophrenia

For individuals that DO NOT WANT to quit smoking:
1. We have opportunities for smokers with mental illness (SCHIZOPHRENIA or BIPOLAR DISORDER)
2. And smokers without mental illness (FOR FAMILIES, STAFF, ETC)

For individuals that DO WANT to quit smoking:
We have opportunities for smokers with SCHIZOPHRENIA or SCHIZOAFFECTIVE DISORDER

For more information call Dr. Williams at 732-235-4600.

Posted: Sept. 2, 2009

  Coping With Depression in Parkinson's Disease

Sponsors and collaborators: University of Medicine and Dentistry New Jersey and National Institute of Neurological Disorders and Stroke (NINDS)

The purpose of this study is to evaluate the efficacy of a cognitive-behavioral treatment, that includes a caregiver-focused social support intervention, for depression in persons with Parkinson's disease.

NJ location:
University of Medicine and Dentistry of New Jersey (UMDNJ), Robert Wood Johnson Medical School,
675 Hoes Lane, Room D-317, Piscataway, NJ 08854
Contact: Roseanne D Dobkin, PhD, 732-235-4051, dobkinro@umdnj.edu

  Recovery from Psychosis: The Impact of Cognitive Coping Strategies on Symptoms, Stress and Arousal Regulation

Sponsors and collaborators: Columbia University and National Institute of Mental Health (NIMH)

This study examines the impact of Cognitive-Behavior Therapy (CBT) on symptoms, physiological arousal, stressors, and the ways to deal with them in individuals with schizophrenia. The primary aim of this study is to investigate the role cognitive coping strategies play in mediating the link between stress, physiological arousal and psychotic symptoms in individuals with schizophrenia during recovery from psychosis. Study ends in 2012.

Contact: David Kimhy, PhD
(212) 543-6817 or kimhyda@pi.cpmc.columbia.edu

CLINICAL TRIALS

  ClinicalTrials.gov - a service of the U.S. National Institutes of Health and a weblink to identify clinical trials seeking participants.  Find clinical trials by state on ClinicalTrials.gov.

  Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

Sponsored by: National Institute of Mental Health (NIMH)

This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia. Patients who do not improve with these medications receive clozapine as their third medication trial.

NJ location: East Orange General Hospital, East Orange, NJ 07018
Contact: Chitra Malur, MD, 973-266-2930, Malurc@evh.org

  Effects of Pentazocine Versus Lorazepam or Placebo on Manic Symptoms

Sponsors and collaborators: Mclean Hospital and Stanley Medical Research Institute

Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms.

NJ location: Jersey Shore Psychiatric Associates, Neptune, NJ 07753
Contact: Peter Harris, MD, PhD

 Attention Deficit Hyperactivity Disorder (ADHD) (Ages 6-17)

This study is designed to determine which of two study medications works best for a given set of AD/HD symptoms (for example; inattention, hyperactivity, impulsivity) in children. Each study medication is approved for the treatment of AD/HD by the Food & Drug Administration (FDA). All participants will be evaluated for AD/HD as well as other psychological conditions, such as depression or anxiety, as part of their assessment. If it is determined that AD/HD is the primary diagnosis, participants will have the opportunity to try each study medication for up to 6 weeks under close clinical observation during weekly visits. Once the optimal dose level and treatment is determined, the participant can continue to receive study medication for three months at no cost. At the end of the study, you will receive a summary of your child’s progress as well as an appropriate referral for continuing treatment.

Contact:
Mount Sinai School of Medicine
1425 Madison Ave. (at 98 St.)
New York, NY 10029
877-ADHD-411
212-659-8833

  National Institute of Mental Health (NIMH) Clinical Trials

  Mood and Anxiety Disorders Program of NIMH clinical research opportunities

  Currently Enrolling Studies at Global Medical Institutes